Market Access Speed Makes the Differences for Pharma

January 12, 2022

Advances in science and legislative changes have accelerated drug discovery and approval in recent years. However, payers eye these drugs with increased skepticism due to ballooning healthcare costs. Therefore, pharma companies must consider market access and commercialization earlier in the development process to increase the odds that payers will cover their drugs. This requires an approach driven by real-world data.

According to Dinesh Kabaleeswaran of Managed Markets Insight & Technology, “With the cost of healthcare and drug discovery continuing to rise and value-based contracting gaining traction, demonstrating a product’s economic value compared to existing competitor products is more important than ever. Drugs today need to be reimbursable, not just approvable. This is a trend that we can see playing out in high-profile drug launches over the past few years.”